apl. Prof. Dr. Jürgen Rech

Einrichtungen, die zum Universitätsklinikum Erlangen gehören Medizinische Fakultät Department of Medicine 3 – Rheumatology and Immunology

MULTI-BIOMARKER DISEASE ACTIVITY AND AUTOANTIBODY STATUS LEAD TO COST EFFECTIVE TAPERING ALGORITHMS IN RHEUMATOID ARTHRITIS PATIENTS IN SUSTAINED REMISSION (2017) Hagen M, Englbrecht M, Haschka J, Reiser M, Kleyer A, Hueber A, Manger B, et al. Conference contribution QUANTIFICATION AND IMPACT OF SECONDARY OSTEOARTHRITIS USING HR-PQCT IN ANTI-CITRULLINATED PROTEIN ANTIBODY RHEUMATOID ARTHRITIS PATIENTS (2017) Figueiredo C, Simon D, Englbrecht M, Haschka J, Kleyer A, Bayat S, Hueber A, et al. Conference contribution Gout mimicking rheumatoid arthritis (2017) Petsch C, Guilhon de Araujo E, Hueber A, Schett G, Manger B, Rech J Journal article, other Elevated Serum Lysophosphatidylcholine in Patients with Systemic Lupus Erythematosus Impairs Phagocytosis of Necrotic Cells In Vitro (2017) Grossmayer GE, Keppeler H, Boeltz S, Janko C, Rech J, Herrmann M, Lauber K, et al. Journal article A patient with ankylosing spondylitis Ein patient mit spondylitis ankylosans (2016) Waltering I, Rech J, Rose O, Derendorf H Journal article Sensitivity and Specificity of Autoantibodies Against CD74 in Early Axial Spondyloarthritis (2016) Witte T, Riechers E, Baerlecken NT, Baraliakos X, Bakhsh KAM, Aries P, Bannert B, et al. Conference contribution Secukinumab Provides Sustained Improvements in the Signs and Symptoms of Active Psoriatic Arthritis through 3 Years: Efficacy and Safety Results from a Phase 3 Trial (2016) Mease PJ, Kavanaugh A, Reimold A, Tahir H, Rech J, Hall S, Geusens P, et al. Conference contribution SECUKINUMAB PROVIDES SUSTAINED IMPROVEMENTS IN THE SIGNS AND SYMPTOMS OF ACTIVE PSORIATIC ARTHRITIS: 2-YEAR EFFICACY AND SAFETY RESULTS FROM THE PHASE 3 RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL, FUTURE 1 (2016) Kavanaugh A, Mease P, Reimold A, Tahir H, Rech J, Hall S, Geusens P, et al. Conference contribution Efficacy and Safety of Tocilizumab in Patients with Giant Cell Arteritis: Primary and Secondary Outcomes from a Phase 3, Randomized, Double-Blind, Placebo-Controlled Trial (2016) Stone JH, Tuckwell K, Dimonaco S, Klearman M, Aringer M, Blockmans D, Brouwer E, et al. Conference contribution INTER SPA: SENSITIVITY AND SPECIFITY OF AUTOANTIBODIES AGAINST CD74 IN EARLY AXIAL SPONDYLOARTHRITIS (2016) Riechers E, Baerlecken NT, Baraliakos X, Bakhsh KAM, Aries PM, Bannert B, Becker K, et al. Conference contribution